The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.
The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with resectable NSCLC.
The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...
No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.
When cancer cells mutate, they produce small peptides called neoantigens. Because neoantigens remain relatively unique to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback